Understanding The Importance Of Panton-Valentine Leukocidin Production In Australian Isolates Of Staphylococcus Aureus.
Funder
National Health and Medical Research Council
Funding Amount
$118,796.00
Summary
New strains of the superbug methicillin-resistant Staphylococcus aureus (MRSA) have emerged in the community, causing severe, sometimes fatal infections in otherwise healthy people. These strains, called community-acquired MRSA produce a toxin (Panton-Valentine leukocidin). This project will provide important information about how this toxin promotes disease, and how the immune system responds to the toxin, providing the basis for the development of immunotherapies against this new superbug.
Rapid Prediction Of Antibiotic Resistance In The Enterobacteriaceae: Making Use Of Restricted Diversity In Mobile Resistance Gene Pools
Funder
National Health and Medical Research Council
Funding Amount
$385,032.00
Summary
Immediate treatment of patients suffering life-threatening bacterial infections with effective antibiotics greatly improves their chances of survival, but antibiotic resistance increasingly complicates this treatment. Currently such resistance cannot be detected in time to help decide the best antibiotic to use. We aim to define a small set of the many known antibiotic resistance genes that can be used accurately predict resistance in rapid tests using modern detection systems.
Antibiotics have different effects on our own bacterial ecology, with sometimes unexpected detrimental effects. In this project, we will study this in detail and particularly address the question of 'good' and 'bad' antibiotics and how to identify them. National antibiotic policy and the deployment of 'decontamination' strategies in the critically ill are directly related issues and we expect to inform these important policy debates.
Genetic And Biochemical Analysis Of The PIM/LAM Biosynthetic Pathway In Mycobacteria.
Funder
National Health and Medical Research Council
Funding Amount
$272,250.00
Summary
Tuberculosis (TB) is one of the most devastating diseases in human history. TB kills approximately two millions people each year worldwide, more than any other disease caused by a single infectious agent. The disease has re-emerged in recent years due to the AIDS epidemic and the appearance of TB bacteria that are not killed by currently available antibiotics. New antibiotics must be developed to combat this global health threat. This requires the identification of targets on the bacteria on whi ....Tuberculosis (TB) is one of the most devastating diseases in human history. TB kills approximately two millions people each year worldwide, more than any other disease caused by a single infectious agent. The disease has re-emerged in recent years due to the AIDS epidemic and the appearance of TB bacteria that are not killed by currently available antibiotics. New antibiotics must be developed to combat this global health threat. This requires the identification of targets on the bacteria on which antibiotics can act. One particularly attractive target is the outer coat of the bacterium. Several existing antibiotics target the bacterial coat, yet the ways in which coat is assembled are poorly understood. Two related compounds in the bacterial coat, and unique to TB bacteria, are called PIMs and LAMs. The structures of these compounds are known, and the compounds appear to be essential for the survival of the bacteria in the human host. However, the mechanisms by which PIMs and LAMs are made by the bacteria are very poorly understood. The aim of our research proposal is to better understand the process by which these compounds are made. If this process can be blocked by an antibiotic, then this represents a potential anti-TB therapy which could save millions of lives worldwide.Read moreRead less
Next Generation Sequencing Of Hepatitis C Virus To Detect Drug Resistance Mutations
Funder
National Health and Medical Research Council
Funding Amount
$39,497.00
Summary
Hepatitis C is the leading cause of liver cancer and liver failure requiring transplantation in Australia. New antiviral drugs set to revolutionise hepatitis C treatment by substantially improving cure rates could be challenged by the development of resistance mutations, which would make these drugs less effective. We aim to develop a practical test to be used routinely to guide clinicians in choosing appropriate anti-viral drugs for their patients.
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE120100071
Funder
Australian Research Council
Funding Amount
$290,000.00
Summary
Chemi–biology computational platform for lead discovery in infectious disease. A challenge in fighting infectious disease is in finding new bioactive compounds. This facility will provide a high performance computational environment designed to accelerate the discovery of quality compounds for use in anti-infective medicine.